BidaskClub upgraded shares of Inovio Pharmaceuticals (NASDAQ:INO) from a hold rating to a buy rating in a research report report published on Wednesday.
A number of other research analysts have also commented on the company. Maxim Group reissued a buy rating and set a $8.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, August 16th. ValuEngine lowered Inovio Pharmaceuticals from a hold rating to a sell rating in a report on Friday, August 24th. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a buy rating in a report on Wednesday, May 16th. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, July 3rd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Inovio Pharmaceuticals currently has a consensus rating of Buy and a consensus price target of $11.25.
INO stock opened at $5.05 on Wednesday. The firm has a market capitalization of $493.17 million, a price-to-earnings ratio of -4.63 and a beta of 1.83. Inovio Pharmaceuticals has a 1 year low of $3.64 and a 1 year high of $7.00.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.27. The company had revenue of $24.45 million for the quarter, compared to analysts’ expectations of $2.13 million. Inovio Pharmaceuticals had a negative return on equity of 71.53% and a negative net margin of 252.95%. equities research analysts anticipate that Inovio Pharmaceuticals will post -1.07 EPS for the current fiscal year.
In related news, CFO Peter Kies sold 35,000 shares of Inovio Pharmaceuticals stock in a transaction dated Tuesday, July 10th. The stock was sold at an average price of $4.44, for a total transaction of $155,400.00. Following the transaction, the chief financial officer now directly owns 97,088 shares of the company’s stock, valued at $431,070.72. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jong Joseph Kim sold 49,060 shares of Inovio Pharmaceuticals stock in a transaction dated Wednesday, September 12th. The stock was sold at an average price of $5.37, for a total value of $263,452.20. Following the transaction, the chief executive officer now directly owns 2,357,554 shares in the company, valued at $12,660,064.98. The disclosure for this sale can be found here. 9.40% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Levin Capital Strategies L.P. grew its holdings in Inovio Pharmaceuticals by 80.5% during the second quarter. Levin Capital Strategies L.P. now owns 37,000 shares of the biopharmaceutical company’s stock worth $145,000 after acquiring an additional 16,500 shares during the period. Swiss National Bank grew its holdings in Inovio Pharmaceuticals by 12.8% during the first quarter. Swiss National Bank now owns 156,400 shares of the biopharmaceutical company’s stock worth $737,000 after acquiring an additional 17,700 shares during the period. New York State Common Retirement Fund grew its holdings in Inovio Pharmaceuticals by 14.3% during the first quarter. New York State Common Retirement Fund now owns 146,243 shares of the biopharmaceutical company’s stock worth $689,000 after acquiring an additional 18,300 shares during the period. Bank of America Corp DE grew its holdings in Inovio Pharmaceuticals by 36.6% during the second quarter. Bank of America Corp DE now owns 114,660 shares of the biopharmaceutical company’s stock worth $449,000 after acquiring an additional 30,740 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its holdings in Inovio Pharmaceuticals by 8.1% during the second quarter. Schwab Charles Investment Management Inc. now owns 445,846 shares of the biopharmaceutical company’s stock worth $1,748,000 after acquiring an additional 33,567 shares during the period. 31.53% of the stock is currently owned by hedge funds and other institutional investors.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines to prevent and treat cancers and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells, as well as is intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza.
Read More: What is intrinsic value?
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.